Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 2Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Brain Neoplasms 23Prostatic Neoplasms 19Carcinoma, Non-Small-Cell Lung 16Lung Neoplasms 11Neoplasm Metastasis 8Melanoma 6Breast Neoplasms 6Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Carcinoma, Renal Cell 4Small Cell Lung Carcinoma 3Meningioma 3Urinary Bladder Neoplasms 2Sarcoma 2Prostate Adenocarcinoma 2Neoplasms 2Kidney Neoplasms 2Head and Neck Neoplasms 2Glioblastoma 2Gastrointestinal Neoplasms 2Colorectal Neoplasms 2Adenocarcinoma of Lung 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Diseases 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Stage II Prostate Adenocarcinoma AJCC v7 1

Interventions

osimertinib 2aflutinib 2Radiotherapy 2rezivertinib 1pembrolizumab 1lenvatinib 1brigatinib 1Tyrosine Kinase Inhibitors 1S 1 (combination) 1Radiosurgery 1Pharmaceutical Preparations 1JDQ443 1Immune Checkpoint Inhibitors 1Gefitinib 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × NSCLC × Radiosurgery × Clear all
NCT05615142 2026-05-11

Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.

Sichuan University

Phase 1 Active not recruiting
9 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡